[Date Prev][Date Next]
[cdn-nucl-l] MDS Nordion - $20 Million to Build New Commercial Cyclotron
MDS Nordion - $20 Million to Build New Commercial Cyclotron
TORONTO, June 24 /PRNewswire/ - New Facility Essential to
Meet Growing Market Demand for Medical Isotopes Toronto,
Ontario, Canada - MDS Nordion, the world leader in the production
of medical radioisotopes, announced that it is investing $20 million
to build a new commercial cyclotron in Vancouver, British
Columbia. The addition of a fourth commercial cyclotron secures
MDS Nordion's capability to meet increasing demand for diagnostic
and therapeutic radioisotopes used daily around the world.
The new cyclotron, which will double MDS Nordion's current
production capacity at the Vancouver site, will be ready for
production in January 2003. This significant increase reinforces
MDS Nordion's ability to serve radioisotope users including
radiopharmaceutical producers, hospitals and clinics worldwide.
"This essential investment demonstrates our ongoing commitment
to nuclear medicine," said Iain Trevena, Senior Vice-President,
Nuclear Medicine at MDS Nordion. "Our new cyclotron is critical to
secure ongoing and reliable worldwide supply for vital medical
In particular, MDS Nordion's cyclotron will help meet growing
demand for the radioisotopes iodine-123 and palladium-103. MDS
Nordion is the largest commercial producer of iodine-123 in North
America and a major supplier to independent researchers. MDS
Nordion is also the leading commercial supplier of palladium-103 to
manufacturers of prostate seed implants.
Iodine-123 is primarily used in the diagnosis of thyroid conditions
such as cancer and neurological disorders such as Alzheimer's
and Parkinson's disease. Palladium-103 is used in treatment of
prostate cancer, the most common form of cancer in men, affecting
over 200,000 men in Canada and the United States each year.
"The medical community relies on MDS Nordion's experience in
producing radioisotopes for the clinical diagnosis and treatment of
patients with cancer, and also cardiac and other disease," said Dr.
Sandy McEwan, Senior Specialist, Nuclear Medicine, Department
of Oncologic Imaging at the Cross Cancer Institute, a leading
Canadian institution for cancer therapy and research. "The
increased supply of iodine-123 and other necessary radioisotopes
will improve the care we can give to our patients."
MDS Nordion supplies over two-thirds of the world's reactor-
produced isotopes and a wide variety of cyclotron-produced
isotopes used in nuclear medicine procedures. It is estimated that
nearly 20 million nuclear medicine procedures are conducted
worldwide each year.
MDS Nordion currently operates two commercial cyclotrons, also
known as particle accelerators, at the TRIUMF site located on the
University of British Columbia campus, and a third in Fleurus,
Belgium. TRIUMF is Canada's centre of excellence for subatomic